Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol.
BACKGROUND
Combination treatment with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy has led to major advances in the treatment of acute promyelocytic leukemia (APL).


METHODS
In this study, we reviewed the outcome of pediatric APL patients treated using a modified AIDA protocol at our institution.


RESULTS
Between May 1999 and December 2007, 23 patients were diagnosed with APL at the Department of Pediatrics, Saint Mary's Hospital, The Catholic University of Korea. Eleven patients were male (48%) (median age at diagnosis, 11 (range, 2-14) years). The treatment protocol consisted of remission induction (achieved by coadministration of ATRA and idarubicin), 3 courses of consolidation treatment, and 2 years of maintenance treatment during which ATRA was also administered. Three patients died early during remission induction due to CNS hemorrhage. The remaining 20 patients achieved complete remission (CR), with an overall CR rate of 87%. Two patients relapsed and died, and another patient died of pneumonia unrelated to APL. Four patients (17%) were diagnosed with ATRA syndrome, and all patients showed resolution of symptoms. The event-free survival (EFS) and overall survival (OS) of the cohort were 78.3±8.6% and 76.3±9.5%, respectively. Initial WBC count at diagnosis was the only significant prognostic factor for the rate of CR (P=0.039) and OS (P=0.039).


CONCLUSIONS
A modified AIDA protocol for the treatment of childhood APL leads to improved EFS and OS, with limited ATRA syndrome-associated toxicity. Active monitoring and treatment of patients with high initial WBC counts may help in reducing mortality.
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Myoung-Hyun
MH
Kim
Cheol-Soon
CS
Choi
Jae Wook
JW
Lee
Pil-Sang
PS
Jang
Nak-Gyun
NG
Chung
Bin
B
Cho
Dae-Chul
DC
Jeong
Hack-Ki
HK
Kim
Best Pract Res Clin Haematol. 2003 Sep;16(3):453-61
12935962
Leukemia. 2003 Feb;17(2):339-42
12592333
Blood. 2005 Jul 15;106(2):447-53
15677559
Cancer Genet Cytogenet. 2000 Apr 15;118(2):169-70
10798868
Pediatr Hematol Oncol. 1998 May-Jun;15(3):243-8
9615322
Leuk Lymphoma. 1993 Sep;11(1-2):27-36
8220153
J Pediatr Hematol Oncol. 2008 May;30(5):387-90
18458575
Blood. 1999 May 15;93(10):3167-215
10233871
J Clin Oncol. 2004 Apr 15;22(8):1404-12
15084614
Cancer Genet Cytogenet. 2010 Mar;197(2):185-8
20193853
Acta Paediatr Jpn. 1995 Jun;37(3):384-7
7645395
J Clin Pharm Ther. 2008 Aug;33(4):331-8
18613850
Curr Treat Options Oncol. 2008 Feb;9(1):95-105
18506629
Blood. 1999 Nov 1;94(9):3015-21
10556184
Acta Haematol. 2010;123(3):162-70
20224268
Haematologica. 2007 Nov;92(11):1519-32
18024401
Genes Chromosomes Cancer. 1997 Feb;18(2):151-3
9115966
Ann Intern Med. 1992 Aug 15;117(4):292-6
1637024
N Engl J Med. 1997 Oct 9;337(15):1021-8
9321529
Blood. 2002 Feb 1;99(3):759-67
11806975
J Clin Oncol. 2005 Oct 20;23(30):7632-40
16234524
Blood. 1996 Aug 15;88(4):1390-8
8695858
J Clin Oncol. 1990 Nov;8(11):1913-21
2230879